Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OTI-20024 is a preclinical-stage therapeutic candidate developed by Ophthalmic Therapeutic Innovation for the treatment of Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION). The product utilizes a specialized intravitreal (IVT) sustained-release rod (implant) to deliver an undisclosed therapeutic agent directly into the vitreous chamber. This delivery modality is designed to provide prolonged therapeutic levels of the drug to the optic nerve head, aiming to mitigate the vision loss associated with NAION. As of current pipeline disclosures, the specific molecular mechanism of action and the identity of the active pharmaceutical ingredient remain proprietary.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on OTI-20024.